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Abstract 
Background: C-terminal agrin fragment (CAF) is a split product of agrin, the major 
proteoglycan of the glomerular base membrane. The involvement of CAF in 
predicting glomerular filtration rate (eGFR) has never been evaluated.  
Material&Methods: We measured/calculated serum CAF-, creatinine-levels and 
eGFR(MDRD) in 96 healthy individuals and in 110 end-stage renal disease (ESRD) 
patients undergoing kidney transplantation before and numerous times after 
transplantation. Correlation between CAF- and creatinine-levels/eGFR was calculated 
as within-patients- (cWP) and between-patients-correlation (cBP). Moreover we 
evaluated the association of CAF with delayed graft function (DGF). CAF’s 
predictive value was compared to creatinine by receiver operating characteristics 
(ROC)-analysis. 
Results: CAF levels strongly correlated with creatinine (r=0.86(cWP), r=0.74(cBP)) 
and eGFR(MDRD) (r=0.86(cWP), r=0.77(cBP)). Pretransplant (pre-Tx) CAF-levels 
were 19-times higher than in healthy individuals (1075.0 (112.0;6397.4) vs. 56.6 
(20.0;109.5) pM). After transplantation, CAF levels decreased significantly faster 
than creatinine levels (postoperative day 1-3 (POD 1-3): 578.0 (101.6;2113.0), 54% 
of pre-Tx levels, creatinine: pre-Tx 6.8 (2.3;15.7) mg/dl, POD 1-3: 6.3 (1.1;12.7), 
93% of pre-Tx levels, p<0.001). Stable serum levels were reached 1-3 months after 
transplantation in CAF and creatinine (CAF: 139.4 (6.7;851.0) pM, 13% of pre-Tx 
levels; creatinine: 1.6 (0.7;8.8) mg/dl, 24% of pre-Tx levels). CAF-levels at POD 1-3 
were significantly associated with DGF and outperformed creatinine in predicting 
DGF (area under the curve(AUC)-CAF: 80.7% (95%-CI: 72.3%-89.1%) vs. AUC-
Creatinine: 71.3% (95%-CI: 61.8%-81.1%, p=0.061)). 
Conclusion: CAF is a new promising biomarker for kidney function. Moreover, it 
may serve as a new tool for the prediction and early detection of DGF.  
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Introduction:  
Serum creatinine and urea are the most reliable biomarkers to monitor kidney 
function (1, 2
1
). Although they have been used over decades and are applied for the 
evaluation of kidney function in the majority of studies, their application is limited: 
they lack sensitivity and specifity, especially in acute changes of kidney function and 
are influenced by multiple parameters such as muscle mass, liver function and 
pharmacological substances ( , 2). Thus, new biomarkers have been evaluated, for 
example cystatin c, human neutrophil gelatinase-associated lipocalin (NGAL), 
Interleukin-18 (IL-18) and Kidney-injury molecule 1 (KIM-1) (3, 4, 5, 6
Neurotrypsin, a serine protease, cleaves agrin, a major heparan sulfate proteoglycan, 
at two homologous sites, liberating a 22-k-Dalton sized C-terminal fragment, called 
“CAF” (
). But so far 
only cystatin c measurements have in part been routinely established. 
7, 8, 9, see suppl 1). Among neuronal and other tissues, agrin is expressed in 
the kidney, where it substantially contributes to the formation of the glomerular 
basement membrane (GBM) (10, 11, 12
This is the first study in that field ever to characterize CAF as a biomarker for kidney 
function in healthy subjects as well as in patients with chronic renal failure. Thus, we 
evaluated serum CAF levels in healthy subjects and in 110 renal transplant recipients 
before and several times after transplantation to correlate CAF levels with kidney 
function. Additionally we addressed the question if early postoperative CAF levels 
could predict a delay of graft function (DGF) in the short term after transplantation. 
), possibly linking it to the podocytes. CAF is 
detectable in human blood. The question rises, if changes of kidney function cause 
changes in CAF serum levels in human. So far CAF has never been scientifically 
explored in nephrological interrogations. 
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Patients and Methods 
Study population 
The study was approved by the local ethic’s committee. All patients enrolled in this 
study gave their consent. The total study population consisted of 206 individuals and 
was based on an observational study concept. Two different groups of patients were 
included in this study: 96 healthy volunteers and 110 patients suffering from chronic 
kidney disease (CKD) undergoing kidney transplantation. 
 
Kidney transplant recipients 
To evaluate the influence of kidney function on CAF levels we included 110 patients 
suffering from CKD or end-stage renal disease (ESRD). Patients underwent kidney 
(living as well as cadaveric donors) or combined kidney-pancreas-transplantation in 
the time from 2007 to 2011 at Klinikum rechts der Isar, Munich, Germany.  Not every 
patient who received a kidney transplant from 2007 to 2011 was enrolled in this 
study. No specific inclusion or exclusion criteria had to be met. All patients received 
an initial triple immunosuppression consisting of a calcineurin-inhibitor (71 
tacrolimus (TAC), 39 cyclosporine (CyA)), mycophenolic acid (MMF) and 
corticosteroids (Tab. 1). In the follow up period 16 patients were switched from CyA 
to TAC, whereas four patients were switched from TAC to CyA. Blood samples were 
obtained right before transplantation and several times up to a median of 128 days 
after transplantation (range 6-1757 days). In total 746 samples were obtained. The 
time points when blood was drawn did not follow a strict protocol, but blood samples 
could be obtained from every patient before and at least once in the early 
postoperative period (postoperative day 1-3, “POD 1-3”). Blood samples were 
categorized into certain time frames after transplantation (Tab. 1). If more than one 
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sample from one patient was obtained in a certain time frame, the mean CAF level 
was calculated and used for statistical work-up.  
All blood samples were analysed for CAF and creatinine levels and estimated 
Glomerular filtration rate (eGFR). The eGFR was calculated for every sample using 
the formula of the MDRD-Trial (13). To analyse patient related parameters that might 
influence CAF levels, age, gender, weight and liver function parameters were 
assessed. At last we assessed the incidence of DGF, defined as the need for at least 
one dialysis treatment within the first week after transplantation (14
 
). The need for 
dialysis treatment was evaluated by the treating physician and did not follow a strict 
protocol.  
Healthy volunteers 
The control group consisted of 96 healthy volunteers. Blood samples were drawn 
once in the morning hours to measure CAF and creatinine levels. 
 
Blood sample measurement of CAF and creatinine levels 
All blood samples were evaluated for CAF levels using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit (NTCAF Elisa Kit, Neurotune, 
Schlieren, Switzerland, (15), see a detailed description there). In brief, 50 µl of blood 
sample need to be mixed with 50 µl of incubation buffer in wells on a Deepwell 
protein Lobind plate. After that 100 µl of 400 nM CAF Calibrator protein solution is 
mixed with 900 µl dilution buffer in order to create a calibrator dilution series on the 
same plate. Then the plate is sealed and incubated in a water bath preheated to 56°C ± 
1°C for 30 min ± 1 min. When finished the plate is centrifuged for 5 min at 3000 x g 
at room temperature. Subsequently 10 µl of sample and dilution series is transferred 
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to a pre-coated micro titer plate, which is already prepared with 90 µl of dilution 
buffer in each well. Now the ELISA plate is incubated for 16 hours at room 
temperature. On the next day an ELISA analysis protocol has to be followed: the plate 
needs to be washed three times, after that 100 µl of CAF detector antibody solution is 
added to each well and incubated for 30 minutes at room temperature. The same step 
is repeated with SA-poly-HRP solution, followed by TMB solution for colour 
development. The results are read out in a plate reader at 450 nm. Data is analysed 
with an excel file supplied by the company. For every sample two ELISAs have to be 
performed and a mean value needs to be calculated. In the following text CAF values 
are expressed as picomol (pM), which corresponds to a concentration of 20 pg/ml. 
Serum creatinine levels were quantified using a well established photometric 
measurement (Jaffe method, normal range 0.7-1.3 mg/dl in males and 0.5-1.1 mg/dl in 
females).  
 
Statistics 
For statistical analysis Excel (Microsoft, Redmond, USA) and SPSS software (SPSS 
Inc., Chicago, USA) were used. The Kolmogorov-Smirnov-Test was performed to 
evaluate the normality of data distribution. Continuous data are expressed as mean 
with standard deviation (SD) or median and range whenever appropriate. Categorial 
variables are reported in absolute numbers and percentages. To assess correlation 
between CAF and creatinine levels/eGFR a within-patient-correlation (cWP, in case 
of at least three samples obtained in one patient) as well as a between-patient-
correlation (cBP) was calculated by using multiple regression (16, 17). Since we 
evaluate several samples in each individual, it can be misleading to analyse the whole 
set of samples as if the data were a simple set of samples. Therefore we tried to 
 7 
answer two questions: we used the cWP to analyse if changes of CAF levels in one 
patient are associated with changes of creatinine levels in order to remove differences 
between patients. To answer the question if patients with high CAF levels also tend to 
have high levels of creatinine we used the cBP. Because the relationship between 
CAF and creatinine as well as eGFR can be linearized by a logarhythmic function, we 
also calculated correlations between logarhythmic CAF and logarhythmic 
creatinine/eGFR, according to the formula y = a * xb that results in a linear 
expression a log(y) = a + b * log(x) and tested this correlation for significance. To test 
if there is a kinetic difference in the decrease of post-operative CAF and creatinine 
levels compared to pretransplant (pre-Tx) levels Wilcoxon-Signed-Rank-Test test was 
used. Univariate analysis (using Spearman-rho test) was performed with CAF levels 
as dependent variable and the following covariables to evaluate if the following 
parameters influence pre-Tx CAF levels: age, gender, weight, alanin-aminotransferase 
(ALAT) and gamma-glutamyl-transferase (GGT). To analyse if there is an association 
of CAF and creatinine levels on POD 1-3 with DGF the Mann-Whitney test was 
performed. Additionally a receiver operating characteristic (ROC) analysis was 
performed to evaluate if CAF is an appropriate marker to predict DGF with accurate 
sensitivity and specifity and compared it to creatinine. A probability (p)<5% was 
considered statistically significant. 
 
Results 
Patients’ demographics 
The mean age of kidney transplant recipients was 51.2±13.5 years, 71 patients were 
male (Tab. 1). 103 patients received single kidney transplantation, in 79 patients a 
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deceased donor organ was transplanted. 40 (36.4%) patients experienced DGF. The 
mean age of healthy volunteers was 47.7±16.0 years, 34 were males (Tab. 1). 
.  
Correlation of CAF and creatinine/eGFR in renal transplant patients 
To assess the correlation of CAF and creatinine levels before and after transplantation 
we calculated the cWP and cBP as described in the statistics part. The cWP was 
r=0.68 (p<0.001, Tab. 2, Fig. 1a). When we calculated the correlation logarhythmic 
CAF and creatinine it was even stronger (r=0.86, p<0.001, Tab. 2, Fig. 1b). The cBP 
was somewhat weaker, but still r=0.55 (p<0.001, Tab. 2) for absolute values and 
r=0.74 (p<0.001, Tab. 2) for logarhythmic data.  
When we compared logarhythmic CAF and eGFR the cWP was r=-0.86 (p<0.001, 
Tab. 2). The cBP was r=-0.77 (p<0.001, Tab. 2, Fig. 2). We did not calculate the 
correlation of absolute values, since the calculation of eGFR from creatinine values 
follows a logarhythmic approach. 
 
Development of CAF levels and creatinine levels/eGFR in kidney transplant 
recipients after transplantation 
Median pre-Tx CAF levels were 19 times higher than in healthy volunteers (1075.0 
(112.0;6397.4) pM vs. 56.6 (20.0;109.5) pM, Tab. 2). Median creatinine levels in 
healthy subjects were 0.78 mg/dl (0.53;1.08). On POD 1-3 there was a 46% decrease 
in median CAF levels (578.0 (101.6;2113.0) pM, p<0.001, Tab. 2, Fig. 3) compared 
to pre-Tx levels. 1-3 months after transplantation CAF levels were around 87% lower 
than pre-Tx levels and 2.5 times higher than in healthy volunteers (139.4 (6.7;851.0), 
p<0.001, Tab.2, Fig. 3a/b). Creatinine levels decreased only by around 7% from 6.8 
(2.3;15.7) mg/dl pre-Tx to 6.3 (1.1;12.7) mg/dl on POD 1-3. 1-3 months after 
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transplantation creatinine levels were 76% lower compared to pre-Tx levels (1.6 
(0.7;8.8) mg/dl, p<0.001, Tab. 2, Fig. 3a/b) and 2.1 times higher than in healthy 
subjects (p<0.001). 
 
Comparison of the development of postoperative CAF and creatinine levels within 
patients 
Comparing the time course of both parameters in each patient, median CAF levels 
decreased significantly faster from pre-Tx to POD 1-3 than creatinine levels (46% vs. 
7%, p<0.001, Fig. 3b). CAF levels again decreased more than creatinine levels from 
POD 1-3 to day 4-10  (53% vs. 38%, p=0.05, Tab. 2, Fig. 3b). From day 4-10 to day 
11-30 the decrease of creatinine was greater (37.1% vs. 48.7%, p>0.05, Tab. 2, Fig. 
3b). From day 11-30 to 31-90 the decrease of both parameters was not significantly 
different any more (CAF: 20% vs. creatinine: 18.4%, p>0.05, Tab. 2, Fig. 3b). After 
that time the development was statistically similar, since at that time a stable level on 
both parameters was reached. When we compared creatinine and CAF levels of each 
time period to pre-Tx levels, CAF levels were significantly lower at each time period 
compared to creatininie levels (p<0.01 for each time period, Fig. 3b).  
 
CAF levels and DGF 
40 (36.4%) patients experienced DGF. When we compared the correlation of pre-Tx 
CAF and creatinine levels with DGF, there was no statistical significant difference 
between both groups (p=0.688 and p=0.828, respectively, Tab. 3). On POD 1-3, CAF 
and creatinine levels were significantly higher in the DGF-group (p<0.001 and 
p=0.001, respectively, Tab. 3):  In the DGF-group, CAF levels decreased around 
19.9%, whereas creatinine levels increased by around 4.4% (Tab. 3). In the group 
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without DGF, CAF levels decreased around 64.6%, whereas creatinine levels 
decreased around 18.9%. In ROC-Analysis CAF levels on day 1-3 were moderately 
accurate in predicting DGF concerning sensitivity and specifity with an area under the 
curve (AUC) of 80.7% (72.3%-89.1%, Fig. 4). It was superior to creatinine with an 
AUC of 71.3% (61.8%-81.1%, p=0.061, Fig. 4). The optimal cut-off value for CAF in 
predicting DGF was 676.5 pM, resulting in a sensitivity of 74.4% and a specifity of 
81.2% (Tab. 4). The optimal cut-off for creatinine was 5.4 mg/dl, resulting in a 
sensitivity of 92.3%, but a specifity of only 50.0% (Tab. 4). 
 
Effect of different parameters on CAF and creatinine levels 
On univariate analysis, median pre-Tx CAF levels in females were significantly 
higher than in males (1206 (112.0;3990.0) pM vs. 983 (259.0;6397.0) pM, p=0.032). 
Age (p=0.985), weight (p=0.547) and liver function (ALAT p=0.547, GGT p=0.461) 
had no major impact on CAF levels.  
 
Discussion 
This is the first study ever demonstrating that CAF could serve as a new and reliable 
biomarker for evaluation and monitoring of kidney function.  
In detail we could firstly show that CAF levels highly correlated to eGFR as well as 
creatinine levels. CAF levels were 19x higher in ESRD patients before transplantation 
compared to healthy subjects. Secondly, CAF levels decreased significantly over a 
period of 4 weeks to reach stable levels at 1-3 months after transplantation. The 
decrease exceeded and was faster than that of creatinine. Thirdly, stable CAF levels 
were lower than creatinine levels compared to pre-Tx levels, indicating a wider range 
of data and therefore higher sensitivity for small changes of kidney function. 
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Fourthly, early postoperative CAF levels were statistically significantly associated 
with DGF and even more predicted DGF with good sensitivity and specifity 
exceeding the values of creatinine.  
The major finding of our study is that CAF levels highly correlated to eGFR and 
creatinine levels. Basically there are two possible explanations for this finding: CAF 
is a cleavage product of agrin, mediated by neurotrypsin, a serine protease. Agrin 
itself is a major component of the synapse and different base membranes, among 
them the GBM (7, 8, 9). Increased CAF levels could be generated either due to 
reduced glomerular filtration or tubular secretion (which is conceivable and also 
possible because of the size of 22 k-Da). This would be analogous to creatinine and is 
likely due to the similar kinetics both biomarkers shown with improving kidney 
function (Fig. 3a/b). Otherwise the cleavage of agrin directly in renal tissue could 
possibly lead to a degradation of the GBM and therefore of the glomerulus itself, 
causing a decline in glomerular function and/or glomerular loss respectively. This 
may as a consequence lead to elevated CAF levels.  
The second finding of our study was the observation of a decrease in CAF blood 
levels with improving graft function after transplantation. In statistical analysis a 
strong correlation of CAF and creatinine levels/eGFR was detected in transplant 
recipients for both the absolute levels and the relative changes after transplantation in 
single patients. In this context the correlation of changes in both parameters exceeded 
the absolute values correlation, indicating a strong dependence of CAF on renal 
function since absolute creatinine values show high intraindividual differences and 
therefore correlations might be biased when comparing absolute values. Interestingly 
the logarhythmic correlation between CAF and creatinine as well as eGFR was higher 
than comparing absolute values. For eGFR, which is being calculated from creatinine 
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blood levels in a logarhythmic approach, this hyperbolic correlation was also 
observed for other biomarkers such a cystatin c, NGAL and creatinine (18, 19, 20, 21, 
22
21
), but correlation of CAF and eGFR in the setting of transplantation was even 
stronger than shown for cystatin c and NGAL ( , 23, 24, 25
20
). Compared to 
creatinine it is remarkable that in the setting of severely reduced renal function (GFR 
<20 ml/min) the percentual change of CAF values with each ml/min of eGFR is much 
higher than in creatinine, ranging from around 200 to 2000 pM, compared to 
creatinine with a smaller variation in this stage of kidney disease. Compared to pre-Tx 
levels, CAF levels were significantly lower in every time period after transplantation 
compared to creatinine. Overall, the range of CAF levels in our study was from 139.4 
pM (median) at stable graft function 1-3 months post-transplant to 1075 pM (median) 
pre-transplant, indicating a variation of nearly 800%, whereas the range of creatinine 
was only half as much at around 400%. This suggests that CAF is a more sensitive 
and faster marker for detection of also smaller changes of renal function, a finding 
that could be of outstanding value. This observation is fortified by the finding that 
CAF levels decreased significantly faster than creatinine in the early postoperative 
phase, whereas creatinine showed a more slothful reaction on improvement of 
transplant function. This results in both markers reaching stable blood levels 1-3 
months after transplantation. Similar observations have been published for cycstatin c 
and NGAL in the setting of kidney transplantation ( , 24, 26, 27) being superior to 
creatinine in early reaction of blood levels on changes of kidney function. But other 
studies failed to show superiority of cystatin c and its calculation formulas as well as 
NGAL over creatinine in reflecting renal function in different settings (28, 29, 30, 
31). Additionally cystatin c levels were observed to rise again in the postoperative 
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period after renal transplantation independently from renal function (26, 32
The third major finding is a significant association of CAF levels on POD 1-3 with 
DGF. CAF levels on day 1-3 after transplantation predicted DGF with higher specifity 
and sensitivity than creatinine. DGF is a major issue in the early postoperative phase, 
since adverse events such as immunologic hazards need to be handled quickly. 
Therefore a sensitive marker is urgently needed. In our collective 36.4% of patients 
experienced DGF. In this group elevated CAF levels on POD 1-3 were significantly 
associated with DGF with being more than twice as high as in the group without 
DGF, whereas creatinine levels only differed by around 20%. Reversely, CAF levels 
decreased by around 63% in the group without DGF, compared to 20% in the DGF 
group. In ROC-analysis, CAF levels on POD 1-3 predicted DGF moderately accurate 
with higher sensitivity and specifity than creatinine at an optimal cut-off value of 677 
pM. Urine NGAL and IL-18 have been evaluated for the same purpose (
), 
therefore limiting its use under these clinical circumstances.  
33, 34, 35), 
often with good results. But serum markers are favoured since urine often is hard to 
assess. Whereas serum IL-18 failed to be of great value for the prediction of DGF in 
renal transplant patients when measured in the blood (36, 37
37
), results on NGAL are 
conflicting ( , 38, 39, 40
37
). Blood cystatin c levels were beneficial in some studies 
( , 41, 42
26
), but failed in other publications to correlate accurately with allograft 
function in the early postoperative phase ( , 32, 43
When we evaluated parameters possibly influencing CAF levels we detected that in 
univariate analysis female sex had slightly higher CAF levels than males. Apart from 
that, neither weight nor age influenced CAF levels. Consindering the influence of 
gender on CAF levels, which is also known for creatinine and cystatin c (
). However, compared to other 
biomarkers CAF appears to be a promising marker in this setting. 
44), CAF 
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seems to be a robust parameter for kidney function independent from individual 
parameters.  
Our study has limitations. It is only based on clinical observative data and does not 
deliver pathophysiological background like glomerular filtration and tubular 
secretion/absorption of CAF. Future studies will have to follow to characterize the 
role of neurotrypsin, CAF and its kinetics on a molecular and histological level. 
Additionally the CAF and creatinine levels assessed were in time frames but not 
specific postoperative days. This would have been desirable to characterize the blood 
level kinetics in a more detailed way.  
Taken together, CAF might be potential new biomarker for kidney function with a 
high level of sensitivity and specifity that could possibily exceed the value of 
creatinine and cystatin c. Additionally CAF might serve as a good clinical biomarker 
to predict DGF accurately in kidney transplant recipients. Based on the results of our 
study, future clinical trials evaluating CAF in different clinical settings such as acute 
kidney failure or chronic diseases should be initiated.  
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Table 1: Kidney allograft recipient’s demographics 
Parameter Result 
  
Age (years, mean +/- SD) 51,2 (+/- 13,5) 
  
Gender (n, %) 110 (100%) 
Male 71 (64.5%) 
Female 39 (35.5%) 
  
Transplantation (n, %) 110 (100%) 
Kidney 103 (93.6%) 
Kidney-pancreas 7 (6.4%) 
  
Kind of donation (n, %) 110 (100%) 
Deceased donor 79 (71.8%) 
Living donor 31 (28.2%) 
  
Underlying renal disease (n, %) 110 (100%) 
Diabetic nephropathy 23 (20.1%) 
Vascular nephropathy 12 (10.9%) 
Autosomal polycystic kidney disease (ADPKD) 11 (10.0%) 
Immunogenic (IgA-Nephropathy,GwP, LE, MPGN) 32 (29.1%) 
Other (hereditary, intersitial disease, unknown) 32 (29.1%) 
  
Immunosuppression – Calcineurininhibitor (n, %)  
Tacrolimus 67 (60.1%) 
Cyclosporine 23 (20.1%) 
Switch from Cyclosporine to Tacrolimus 16 (14.5%) 
Switch from Tacrolimus to Cyclosporine 4 (3.6%) 
  
Patients with delayed graft function (n, %)) 40 (36.4%) 
  
Samples obtained in total (n, %) 746 (100%) 
Before transplantation 110 (14.7%) 
1-3 days after transplantation 127 (17.0%) 
4-10 days after transplantation 131 (17.6%) 
11-30 days after transplantation 98 (13.1%) 
30-89 days after transplantation 123 (16.5%) 
90-179 days after transplantation 88 (11.8%) 
6-12 months after transplantation 48 (6.4%) 
>12 months after transplantation 21 (2.8%) 
Data are presented as absolute numbers (n) and percentrage (%) in brackets; SD = 
stan-dard deviation; GwP = granulomatosis with polyangiitis; LE = Lupus 
erythematodes; MPGN = membranoproliferative Glomerulonephritis; 
Table 2: CAF levels, creatinine levels and eGFR (MDRD) in renal transplant recipients before and after transplantation 
Data are presented as median (minimum;maximum); cWP = within-patient-correlation; cBP = between-patient-correlation; CAF = C-terminal agrin fragment; 
eGFR = estimated glomerular filtration rate; pM = picomolar; mg/dl = miligrams/decilitre; ml/min = mililitre/minute; Tx = transplantation; *p<0.001; 
 
Samples CAF (pM) creatinine (mg/dl) 
cWP  
CAF-creatinine 
cBP  
CAF-creatinine 
eGFR  
(MDRD, ml/min) 
cWP 
CAF-eGFR 
cBP 
CAF-eGFR 
Before Tx 1075.0 (112.0;6397.4) 
6.8  
(2.3;15.7) 
absolute 
0.68* 
absolute 
0.55* 
8  
(4;25) 
logarhythmic 
-0.86* 
logarhythmic 
-0.77* 
day 1-3 578.0 (101.6;2113.0) 
6.3  
(1.1;12.7) 
9  
(4;55) 
day 4-10 271.6 (57.1;1933.0) 
3.9 
 (0.7;17.6) 
17  
(4;106) 
day 11-30 170.9 (46.2;1337.0) 
2.0 
(0.8;10.0) 
36  
(6;111) 
day 31-90 139.4 (6.7;851.0) 
1.6  
(0.7;8.8) 
logarhythmic 
0.86* 
logarhythmic 
0.74* 
43 
 (7;130) 
day 91-180 151.3 (13.7;509.0) 
1.8  
(0.7;5.0) 
40  
(12;130) 
day 181-365 143.6 (11.3;483.1) 
1.6  
(0.7;3.7) 
43  
(14;129) 
more than 365 
days 
140.5 
(46.3;287.6) 
1.7  
(0.9;2.5) 
44 
(22;78) 
 
Table 3: CAF and creatinine levels in patients with and without delayed graft function 
Data are presented in median (minimum;maximum); DGF = delayed graft function; w/o = without;  
CAF = C-terminal agrin fragment; n = number of patients; pre-Tx = pre-transplant; POD = 
postoperative day; pM = picomolar; mg/dl = miligrams/decilitre; 
 
 
 
 Patients with DGF Patients w/o DGF p value 
n 40 70  
pre-Tx CAF levels (in pM) 1137 (366;2133) 1031 (258;6397) 0.688 
POD 1-3 CAF levels (in pM) 911 (271.7;1763) 364.6 (102;2113) <0.001 
pre-Tx creatinine levels (in mg/dl) 6.8 (3.7;15.7) 6.9 (3.1;14.2) 0.828 
POD 1-3 creatinine levels (in mg/dl) 7.1 (2.9;12.7) 5.6 (1.7;12.5) 0.001 
Table 4: Sensitivity and specificity of different CAF and creatinine cut-off 
values on POD 1-3 for predicting DGF 
CAF = C-terminal agrin fragment; POD = postoperative day; DGF = delayed graft 
function; pM = picomolar; mg/dl = miligrams/decilitre; 
 
 
 
Biomarker Cut-off level Sensitivity Specifity 
CAF (in pM) 1304.5 15.4% 95.7% 
 676.5 74.4% 81.2% 
 283.5 97.4% 37.7% 
Creatinine (in mg/dl) 9.6  15.4% 95.7% 
 5.4  92.3% 50.0% 
 3.5  97.4% 12.9% 
 
  

 
  
 
 
 
